Among the 17 analysts covering Spyre Therapeutics, Inc. (SYRE), Deutsche Bank stands out with the most bullish 12-month price target of $135. That figure, reiterated in June 2026 when the firm raised its target from $115, represents the ceiling of Wall Street expectations for this clinical-stage biotechnology company. With the stock recently closing at $101.50, reaching $135 would require a gain of roughly 33% — a meaningful move that has captured the attention of growth-oriented biotech investors.
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, as well as rheumatic conditions. The company's pipeline includes SPY001, an anti-α4β7 monoclonal antibody in Phase 2 trials; SPY002 and SPY072, both anti-TL1A antibodies; and SPY003, which targets IL-23. Beyond single-agent programs, Spyre is advancing combination approaches — SPY120 (anti-α4β7 plus anti-TL1A), SPY130 (anti-α4β7 plus anti-IL-23), and SPY230 (anti-TL1A plus anti-IL-23) — that could differentiate it in a crowded immunology landscape.
SYRE has delivered one of the most dramatic biotech rallies of the past year. The stock has surged from a 52-week low of $14.51 to recent levels above $100, boosting its market capitalization to approximately $8.8 billion. The move reflects growing confidence in the company's pipeline and the enormous commercial opportunity in IBD, where established therapies still leave many patients underserved. However, investors should note that Spyre remains a pre-revenue company — its last reported earnings per share (EPS) came in at -$0.74, and the company is not expected to generate meaningful product sales in the near term. A price-to-book ratio of approximately 16.5 highlights the premium valuation the market has assigned to its pipeline promise.
Several factors could propel Spyre Therapeutics toward Deutsche Bank's $135 target. Positive Phase 2 data for SPY001 or any of the combination programs would likely serve as the most powerful catalyst, potentially validating the company's approach to developing extended half-life antibodies for chronic inflammatory conditions. The IBD market represents a multi-billion-dollar commercial opportunity, and Spyre's combination strategy could position it to capture market share from established players if clinical data demonstrate superior efficacy.
Institutional conviction provides another tailwind. Over 90% of SYRE shares are held by institutions, and major ETFs including the SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) maintain exposure. Recent analyst activity has been overwhelmingly positive: Mizuho raised its target to $120 in July 2026, BTIG maintains a $112 target, and multiple firms have reiterated Buy ratings following the latest clinical updates.
The path to $135 faces substantial hurdles. As a clinical-stage biotech, Spyre carries binary risk: disappointing trial results could trigger sharp reversals. The stock's 3.02 beta underscores its extreme sensitivity to both company-specific news and broader market sentiment. A short float near 20% indicates that a significant portion of market participants are betting against the stock, which can amplify both upside squeezes and downside pressure.
Cash burn remains a persistent concern. With no approved products generating revenue, Spyre funds operations through capital markets — a reality that introduces dilution risk for existing shareholders. The company has already increased its share count by nearly 30% in the past year, and further equity raises could weigh on per-share valuation. Competitive pressure from larger immunology players with established commercial infrastructures and deeper pipelines also cannot be ignored.
The analyst community overwhelmingly favors SYRE, with 16 of 17 analysts rating the stock Strong Buy or Buy and only one dissenting voice. The average 12-month price target sits near $105.79, just modestly above current levels. Targets span from a low of $78 to Deutsche Bank's high of $135, reflecting genuine disagreement about how much of the pipeline's potential is already priced in. Notably, Mizuho's $120 target and BTIG's $112 suggest that even more conservative bullish analysts see room for double-digit percentage gains. The wide spread between the low and high targets — roughly $57 — signals unusually high uncertainty, typical for a clinical-stage biotech whose valuation hinges on future trial results rather than current fundamentals.
From a technical perspective, SYRE currently trades just below its 52-week high of $105.09. A breakout above that level would establish a new all-time high and could open a path toward the psychologically important $120 and $135 zones. The stock's 200-day moving average sits near $56, reflecting how far and how fast the rally has extended. Key support levels to watch include the $80–$85 region, which aligns with the lower end of analyst targets and previous consolidation zones. A failure to hold above $90 on any significant pullback could signal a broader trend shift.
Navigating a high-volatility biotech like Spyre Therapeutics requires timely, data-driven decision-making. Tickeron's AI Daily Buy/Sell Signals leverage artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-powered analysis. Traders can use these signals to identify emerging opportunities, manage existing positions with greater confidence, and stay ahead of shifting market dynamics without spending hours on manual chart analysis. Explore how AI-driven insights can complement your research process and help you respond more efficiently to market changes.
The $135 price target for Spyre Therapeutics is ambitious but not implausible. Achieving it would likely require positive clinical data from SPY001 or one of the combination programs, continued analyst support, and a favorable macro environment for high-beta biotech names. The strength of institutional backing and the enthusiastic analyst consensus provide a solid foundation, but the stock's pre-revenue status, ongoing cash burn, and binary clinical risk mean the journey is far from guaranteed. Investors should watch upcoming trial data readouts, the August 4 earnings report for pipeline updates, and whether SYRE can decisively break above its 52-week high near $105 as an early technical signal. While the target remains within reach based on current Wall Street modeling, the wide range of analyst estimates underscores the reality that outcomes — both positive and negative — can diverge sharply from consensus expectations in clinical-stage biotechnology.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsA.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.
| Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
|---|---|---|---|---|
| SYRE | 100% | -2.15% | ||
| ORKA - SYRE | 50% Loosely correlated | +0.67% | ||
| APGE - SYRE | 48% Loosely correlated | -0.07% | ||
| IMVT - SYRE | 46% Loosely correlated | -1.83% | ||
| RCKT - SYRE | 44% Loosely correlated | -2.05% | ||
| PMN - SYRE | 44% Loosely correlated | +2.00% | ||
More | ||||